FDA Fully Approves Mirvetuximab Soravtansine-Gynx for FR Alpha--Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

The article focuses on the Food and Drug Administration (FDA) full approval of mirvetuximab soravtansine-Gynx for treating FR alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Topics include the drug's effectiveness, its approval process, and its potential impact on treatment options for these cancers.